Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-6-29
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0007-0963
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
132
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
168-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7756145-Adrenergic beta-Antagonists,
pubmed-meshheading:7756145-Aged,
pubmed-meshheading:7756145-Female,
pubmed-meshheading:7756145-Humans,
pubmed-meshheading:7756145-Male,
pubmed-meshheading:7756145-Middle Aged,
pubmed-meshheading:7756145-Skin Pigmentation,
pubmed-meshheading:7756145-Vitiligo
|
pubmed:year |
1995
|
pubmed:articleTitle |
Beta-adrenergic blocking drugs may exacerbate vitiligo.
|
pubmed:publicationType |
Letter
|